CD40 ligand level – vascular inflammation activity and long6term prognosis in coronary heart disease patients

Abstract

Aim. To study prognostic value of plasma soluble CD40 ligand (sCD40L) level in patients with various coronary heart disease (CHD) forms.Material and methods. In total, 65 CHD patients were examined, including 26 with stable effort angina (SEA), functional class (FC) I6III; 23 – with unstable angina (UA), Stage II6IIIB; 15 – with myocardial infarction (MI). Levels of sCD40L, highly sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), and fibrinogen were measured. Follow-up period lasted for 24 months. End-points included death from any cause, non6fatal MI, ischemic stroke, myocardial revascularization, hospitalization due to SEA progression or UA development.Results. In SEA, UA and MI patients, sCD40L levels were similar. Type 2 diabetes mellitus (DM-2) patients had significantly higher sCD40L levels, comparing to other CHD participants. Cardiovascular event (CVE)-free survival analysis demonstrated that in CHD patients with low sCD40L levels, survival was significantly better than in participants with its higher levels, even after DM-2 patients' exclusion.Conclusion. In CHD patients, initially increased sCD40L level is an independent predictor of adverse CVE during two-year follow-up.

Keywords

• soluble сd40 ligand form
• coronary heart disease
• survival
• adverse cardiovascular events